123 related articles for article (PubMed ID: 30323662)
1. Cost-effectiveness analysis of adjuvant treatment for resected pancreatic cancer in China based on the ESPAC-4 trial.
Huang J; Liao W; Zhou J; Zhang P; Wen F; Wang X; Zhang M; Zhou K; Wu Q; Li Q
Cancer Manag Res; 2018; 10():4065-4072. PubMed ID: 30323662
[TBL] [Abstract][Full Text] [Related]
2. S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial.
Liao W; Huang J; Zhu G; Zhou J; Wen F; Zhang P; Zhou K; Wu Q; Wang X; Gou H; Li Q
Expert Rev Pharmacoecon Outcomes Res; 2020 Feb; 20(1):133-138. PubMed ID: 31597496
[No Abstract] [Full Text] [Related]
3. Cost-effectiveness analysis of capecitabine plus bevacizumab versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer from Chinese societal perspective.
Zhang PF; Wen F; Zhou J; Huang JX; Zhou KX; Wu QJ; Wang XY; Zhang MX; Liao WT; Li Q
Clin Transl Oncol; 2020 Jan; 22(1):103-110. PubMed ID: 31062173
[TBL] [Abstract][Full Text] [Related]
4. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer.
Peng J; Tan C; Zeng X; Liu S
PLoS One; 2018; 13(6):e0199553. PubMed ID: 29953476
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
[TBL] [Abstract][Full Text] [Related]
7. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer.
Le QA; Bae YH; Kang JH
Breast Cancer Res Treat; 2016 Oct; 159(3):565-73. PubMed ID: 27572338
[TBL] [Abstract][Full Text] [Related]
9. A cost-effectiveness analysis of capecitabine maintenance therapy versus routine follow-up for early-stage triple-negative breast cancer patients after standard treatment from a perspective of Chinese society.
Li JB; Lin ZC; Wong MCS; Wang HHX; Li M; Li S
BMC Med; 2022 Sep; 20(1):320. PubMed ID: 36156186
[TBL] [Abstract][Full Text] [Related]
10. Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand.
Permsuwan U; Thongprasert S; Sirichanchuen B
Value Health Reg Issues; 2020 May; 21():9-16. PubMed ID: 31634796
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility analysis of 5-fluorouracil and capecitabine for adjuvant treatment in locally advanced rectal cancer.
Katanyoo K; Chitapanarux I; Tungkasamit T; Chakrabandhu S; Chongthanakorn M; Jiratrachu R; Kridakara A; Townamchai K; Muangwong P; Tovanabutra C; Chomprasert K
J Gastrointest Oncol; 2018 Jun; 9(3):425-434. PubMed ID: 29998007
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of utidelone plus capecitabine for metastatic breast cancer in China.
Liao M; Jiang Q; Hu H; Han J; She L; Yao L; Ding D; Huang J
J Med Econ; 2019 Jun; 22(6):584-592. PubMed ID: 30808230
[No Abstract] [Full Text] [Related]
13. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
14. Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer.
Chongqing T; Liubao P; Xiaohui Z; Jianhe L; Xiaomin W; Gannong C; Siying W; Lihui O; Ziying Z
Pharmacoeconomics; 2014 Mar; 32(3):235-43. PubMed ID: 23709451
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer.
Wu Q; Wang X; Zhang M; Liao W; Wang F; Li Q
Oncol Res Treat; 2020; 43(4):153-159. PubMed ID: 32187596
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of first-line adjuvant chemotherapies for resectable gastric cancer patients in China.
Tan C; Peng L; Zeng X; Li J; Wan X; Chen G; Yi L; Luo X; Zhao Z
PLoS One; 2013; 8(12):e83396. PubMed ID: 24340099
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial.
Zhan M; Zheng H; Yang Y; He Z; Xu T; Li Q
Cancer Manag Res; 2020; 12():12919-12926. PubMed ID: 33364840
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomic Evaluation of Erlotinib for the Treatment of Pancreatic Cancer.
Bao K; Li X; He X; Jian L
Clin Ther; 2021 Jun; 43(6):1107-1115. PubMed ID: 34059328
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of adjuvant FOLFOX and 5FU/LV chemotherapy for patients with stage II colon cancer.
Ayvaci MU; Shi J; Alagoz O; Lubner SJ
Med Decis Making; 2013 May; 33(4):521-32. PubMed ID: 23313932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
